Patent Cliffs Meets the GLP-1 Liquidity Wave: Is Pharma the new exit route for Digital Health?
- Nelson Advisors
- 3 minutes ago
- 12 min read
Evaluating Biopharma as an Exit Route for Digital Health
The biopharmaceutical and digital health sectors are undergoing a structural convergence driven by asymmetric financial pressures, shifting commercial models, and evolving regulatory frameworks. Biopharma is entering an aggressive loss of exclusivity (LOE) cycle, frequently designated the "super patent cliff," in which an estimated $200 Billion to $300 Billion in annual global branded revenues will expire between 2025 and 2030. This impending revenue contraction coincides with an unprecedented accumulation of cash reserves among metabolic market leaders, catalysed by global demand for glucagon-like peptide-1 (GLP-1) receptor agonists.
Concurrently, the digital health ecosystem has completed a necessary recalibration following the post-pandemic valuation correction. While digital health venture capital deployment rebounded to $14.2 Billion in 2025 and $7.4 Billion in the first half of 2026, capital distribution has become sharply bifurcated. Private venture-backed exits through initial public offerings (IPOs) remain constrained to a small cohort of scaled, highly profitable enterprises. Consequently, mergers and acquisitions (M&A) have assumed an overwhelming majority of exit liquidity, representing over 94% of all digital health exits.
This environment prompts a critical strategic question for institutional investors, biopharma corporate development leads and healthcare founders: Is biopharma emerging as the primary exit route for digital health?
While biopharma is not replacing traditional digital health consolidators, such as venture backed scale-ups executing venture-to-venture rollups and private equity firms targeting fee-for-service cash flows, it has evolved into a strategic, high value acquirer and commercial platform partner for specific digital health vectors. Driven by the operational necessity to dis-intermediate prescription delivery, maximise GLP-1 patient lifetime value (LTV) through software-driven adherence and accelerate clinical pipeline development to offset revenue cliffs, biopharma is actively extending its acquisition and investment footprint into digital operating layers, specialised clinical care networks and artificial intelligence (AI) infrastructure.
The Digital Health Exit Architecture: Consolidation, Bifurcation and Valuation Rationalisation
Between January 2023 and December 2025, the digital health market processed 620 venture exits generating a cumulative value of $36.3 Billion. Rather than reflecting a stagnant market, the landscape has stabilized into a sustainable, performance driven baseline. Total digital health exit value expanded 10.6% in 2025 to $13.9 Billion, supported by sustained corporate M&A. In the first half of 2026, transaction velocity accelerated further, recording 115 completed acquisitions, with the second quarter logging 71 finalised deals, the highest single quarter transaction volume since late 2021.
Despite this rise in deal volume, capital concentration has reached historic highs. In 2025, mega deals ($100 million or greater) captured 42% of all deployed capital. This concentration intensified in the first half of 2026, where just 8% of completed transactions (20 mega deals) absorbed 45% of total venture funding. This capital profile has established a structural market bifurcation:
The Scaled Winner Class: High growth platforms possessing hard-to-replicate operational assets, such as proprietary clinical provider networks, compounding real-world data assets, and high free-cash-flow margins, continue to command premium valuations. Companies like Hinge Health have demonstrated public market sustainability by comfortably clearing the "Rule of 40" benchmark backed by strong free cash flow margins, while scaled consumer platforms like Whoop and Oura eye public listings.
Distressed Point Solutions: Roughly 35% of digital health financing rounds in 2025 were flat or down-rounds, with unlabeled extensions remaining elevated at 34%. Single use point solutions lacking direct Electronic Health Record (EHR) workflow integration or defensible enterprise distribution are increasingly forced into discounted acquisitions, venture to venture rollups, or asset liquidations.
Market Metric | 2024 Baseline | 2025 Performance | H1 2026 Trajectory | Strategic Implication |
Total Venture Capital | $10.5 Billion | $14.2 Billion | $7.4 Billion | Sustainable capital deployment centered on AI and workflow integration. |
Mega Deal Capital Share | 22% | 42% | 45% | Outsized capital concentration into platform category leaders. |
M&A Deal Volume | 121 Deals | 195 Deals | 115 Deals | M&A firmly established as the primary exit mechanism over public listings. |
Primary M&A Acquirer Class | Digital Health (53%) | Digital Health (66%) | Digital Health / PE / Pharma | Venture-to-venture consolidation dominates general digital health transactions. |
Public Market Exits | 0 IPOs | 5 IPOs | Active Filings (e.g., Oura S-1) | Public market windows open strictly for scaled, highly profitable entities. |
Venture to venture consolidation accounted for 68% of all digital health acquisitions in 2025 as well capitalised platforms acquired specialised technical capabilities, customer contracts and talent. Private equity represented the second most active acquirer class at 10%, focusing heavily on cash flow generative assets in revenue cycle management (RCM) and enterprise clinical workflow automation.
However, biopharma's emerging involvement as a buyer, strategic anchor and commercial partner introduces a distinct value driver into the M&A landscape.
The Biopharma Capital Paradox: Patent Cliffs Meets the GLP-1 Liquidity Wave
To evaluate biopharma’s capacity and appetite for digital health acquisitions, two opposing financial dynamics across the pharmaceutical industry must be analysed: the revenue contraction from primary patent expirations and the rapid cash generation from metabolic therapeutic platforms.
The pharmaceutical industry is navigating its largest patent cliff in history. Between 2025 and 2030, primary compound patents and regulatory exclusivities covering an estimated 68 to 190 blockbuster drugs will expire, exposing $200 Billion to over $300 Billion in annual branded revenue to generic and bio-similar competition. The concentration of these expirations between 2026 and 2028 creates an immediate top-line replacement challenge for legacy pharmaceutical leaders.
Merck & Co., for example, derived approximately 57% of its $65 Billion 2025 top line from Keytruda ($31.7 Billion) and Gardasil 9 ($5.2 Billion), both of which face loss of exclusivity around 2028. Similarly, Bristol Myers Squibb faces concurrent expirations for Eliquis ($14.4 Billion in 2025) and Opdivo ($10.1 Billion in 2025).
Because the all-in cost of developing a novel therapeutic in-house ranges from $3 Billion to $4 Billion across a 10-to-15-year timeline when accounting for clinical failure rates, internal R&D pipelines alone are statistically incapable of refilling these revenue voids in time. Consequently, biopharma executives are forced to deploy capital into external asset acquisitions to preserve top-line expansion.
In stark contrast to the revenue cliffs facing oncology and immunology portfolios, manufacturers of metabolic therapies are experiencing rapid capital accumulation. The market leaders in the GLP-1 landscape, Novo Nordisk and Eli Lilly are generating unprecedented cash flows from diabetes and obesity franchises. Novo Nordisk generated DKK 309 Billion ($44+ Billion) in total net sales in 2025, anchored by 31% constant-exchange-rate (CER) growth in its Obesity Care segment.
This momentum continued into Q1 2026, driven by the launch of its daily oral semaglutide formulation (Wegovy pill), which logged over 2 million prescriptions in its initial quarter. Eli Lilly has driven similar volume trajectories through its injectable tirzepatide portfolio (Zepbound and Mounjaro) and the rollout of its oral GLP-1 candidate Foundayo (orforglipron).
Company / Molecule | Therapeutic Focus | LOE / Expiration Window | 2025 Financial Baseline | Strategic Capital Allocation Priorities |
Merck & Co. (Keytruda) | Immuno-Oncology | 2028 LOE Window | $31.7 Billion Sales | Acquiring late-stage clinical assets and AI discovery engines to offset oncology cliffs. |
Bristol Myers Squibb (Eliquis) | Cardiovascular | 2026–2028 LOE Window | $14.4 Billion Sales | External pipeline diversification and real-world evidence platform acquisitions. |
Novo Nordisk (Wegovy / Ozempic) | Metabolic / Obesity | Exclusivity Protected >2032 | DKK 309 Billion Sales | Direct-to-consumer distribution rails, digital adherence platforms, and NovoCare infrastructure. |
Eli Lilly (Zepbound / Foundayo) | Metabolic / Obesity | Exclusivity Protected >2030s | Double-Digit Volume Expansion | Scaling LillyDirect cash-pay portals, employer platforms, and biometric tracking partnerships. |
Despite rapid volume expansion, biopharma faces structural commercial headwinds that threaten long-term profit margins on GLP-1 therapies. In response to policy shifts and federal pricing agreements, biopharma leaders agreed to framework adjustments, such as Most Favoured Nation pricing and expanded Medicare Part D pilots, that contributed to a 4% to 11% decline in CER realised prices across US commercial channels in Q1 2026. Furthermore, Pharmacy Benefit Manager (PBM) rebate extractions consume a substantial portion of gross list prices.
To protect operating margins, biopharma must maximize prescription volume, disintermediate traditional distribution bottlenecks, and prevent early patient drop-off. Real-world data indicates that a significant percentage of patients discontinue GLP-1 therapy within 12 months due to gastrointestinal side effects, muscular loss, cost barriers, or administrative supply friction. Because GLP-1s require sustained administration to maintain chronic metabolic efficacy, early discontinuation directly degrades patient lifetime value. To defend these high-margin franchises, metabolic market leaders are deploying cash surpluses into digital platforms that automate adherence, track physiological metrics, and establish direct relationships with consumers and self-insured employers.
Strategic Vectors of Biopharma Acquisition Appetite
The intersection of biopharma’s capital allocation priorities and digital health’s operational capabilities has established three primary vectors for acquisition, strategic equity investments and deeply integrated joint ventures.
Direct-to-Patient Distribution Rails and PBM Disintermediation
The establishment of direct to consumer (DTC) digital healthcare platforms, most notably Eli Lilly’s LillyDirect and Novo Nordisk’s NovoCare, marks a structural shift in pharmaceutical distribution. By building vertically integrated digital platforms, biopharma manufacturers connect patients directly to independent telehealth providers, digital pharmacy engines, and direct-to-door fulfilment networks.
This direct to patient architecture provides distinct commercial advantages. By offering cash-pay prescription options (ranging from $149 to $449 per month for oral formulations and discounted cash tiers) directly to consumers, manufacturers capture a larger percentage of the end dollar while bypassing intermediate PBM fee extractions.
Simultaneously, embedding clinical evaluation directly into virtual workflows reduces onboarding friction, accelerating new patient starts. Furthermore, direct consumer touch points generate granular data on fill status, refill timing, and dropout points, providing biopharma with un-aggregated insight into real-world commercial performance.
To operationalise these platforms, biopharma relies on digital health infrastructure partners. Eli Lilly partnered with telehealth operator Form Health to power the intake layer of LillyDirect, while integrating specialised digital pharmacy engines like GiftHealth, Eversana, Truepill and Amazon Pharmacy to fulfil home deliveries.
Similarly, Novo Nordisk integrated Form Health into its NovoCare employer platform, establishing flexible benefit models that offer predictable medication pricing alongside clinician-led wraparound support. Digital health assets that provide the underlying infrastructure for direct drug distribution represent high-priority strategic partners and potential acquisition targets for biopharma.
Clinical Care Management, Biometric Adherence, and LTV Optimisation
Prescription volume alone does not guarantee long-term therapeutic revenue if patient drop-off rates remain high. Consequently, biopharma is incentivised to integrate its molecules with multidisciplinary care models that support long term behavioural change and side effect management.
The digital health M&A market has logged intensive activity across metabolic layers and cardiometabolic clinical management. Platforms offering physician led care, incorporating American Board of Obesity Medicine (ABOM) certified clinicians, advanced practice registered nurses, and registered dieticians, have attracted substantial capital.
This trend is evidenced by major capital deployments across the metabolic layer:
Form Health: Expanded its integrations across Lilly Employer Connect and NovoCare, delivering clinical care models that utilise severity-aware prescribing protocols, side effect mitigation, and lifestyle intervention to maximise therapeutic adherence.
eMed: Secured a $200 Million Series A financing at a $2B+ valuation to scale its employer focused GLP-1 telehealth platform, leveraging agentic AI and capitated care models to manage population level metabolic risk.
Nourish and Midi Health: Raised $100 Million Series rounds to scale specialised clinical networks that combine nutritional therapy and midlife cardio-metabolic care with prescription management.
Biopharma is also pursuing biometric tracking to monitor patient health outside traditional clinical settings. The strategic collaboration between LillyDirect and ŌURA (maker of the Oura Ring) illustrates this approach. By combining continuous physiological tracking, such as sleep patterns, recovery metrics, heart rate variability and body composition changes, with GLP-1 therapy, biopharma can quantify real world therapeutic outcomes.
This biometric data helps demonstrate that weight loss reflects fat mass reduction rather than lean muscle wasting, providing the clinical evidence required to defend coverage claims with commercial payers and enterprise employers.
TechBio, AI Discovery, and Real World Evidence Infrastructure
To mitigate the revenue impact of upcoming patent expirations, biopharma is acquiring software, data and AI assets to modernise its R&D engines. Deal volume across TechBio and AI-driven platforms expanded 81% in 2025, driven by biopharma's urgency to compress discovery timelines and improve clinical trial success rates. Across 2025 and H1 2026, AI-enabled digital health enterprises captured 54% of total venture capital funding, commanding a 19% premium on average deal size compared to non-AI peers (and up to a 61% premium at Series C).
Biopharma acquirers prioritise three specific categories of technology assets:
Generative & Agentic AI Medical Search Engines: Platform investments, such as OpenEvidence closing a $250 Million round backed by over 40% daily physician penetration, illustrate biopharma's focus on platforms that influence clinical decision-making at the point of care.
Multimodal Real-World Evidence (RWE) Networks: Public market outperformers like Tempus, which reported 36% year-over-year revenue growth in Q1 2026 driven by its multimodal clinical-genomic data assets, demonstrate the value of data networks that assist biopharma in patient stratification, biomarker discovery, and post market surveillance.
RNA Delivery and Genetic Platforms: Large-scale transactions, such as Novartis acquiring Avidity Biosciences for $12 Billion, demonstrate that biopharma is willing to pay significant premiums for underlying platform technologies capable of generating continuous pipelines of targeted therapies.
Digital Health Sub-Sector | Primary Strategic Acquirer / Partner | Strategic Rationale | Key Market Transactions & Partners |
DTC Telehealth & Pharmacy Rails | Biopharma Commercial Organisations | PBM disintermediation, lower onboarding friction, cash-pay margin expansion. | LillyDirect, NovoCare, GiftHealth, Form Health. |
Cardiometabolic Care Wraparounds | Biopharma & Enterprise Employers | Side-effect management, adherence extension, LTV maximization. | Form Health, eMed ($200M round), Nourish ($100M), Midi ($100M). |
Biometric Wearables & Health Tracking | Biopharma Digital Health Units | Continuous outcome tracking, lean mass retention evidence, real-world data. | ŌURA / LillyDirect Collaboration. |
AI Medical Search & Decision Engines | Biopharma Commercial & Medical Affairs | Point-of-care clinician engagement, educational deployment. | OpenEvidence ($250M Series D). |
Multimodal RWE & TechBio Platforms | Biopharma R&D / Corporate Development | Pipeline refill, clinical trial acceleration, target validation. | Tempus, Novartis / Avidity Biosciences ($12B). |
Structural Limitations: Why Biopharma Is Not a Universal Exit Route
While biopharma's strategic engagement with digital health has expanded significantly, characterizing biopharma as the universal exit route for the entire digital health sector oversimplifies broader market dynamics. Biopharma corporate development teams evaluate digital health assets through a strict strategic lens. They generally do not acquire software companies simply to capture low-margin software-as-a-service (SaaS) revenue. Instead, biopharma buys or partners with digital health companies when those assets directly protect, optimise, or scale multi billion dollar therapeutic franchises.
As a result, biopharma's acquisition appetite is concentrated in specific sub-sectors:
For software assets outside biopharma's strategic focus, traditional exit channels remain dominant. Private equity firms continue to drive consolidation in administrative and financial workflow solutions, highlighted by major transactions such as the $12 Billion acquisition of Ensemble Health by the Thoreau Group.
Simultaneously, venture backed digital health platforms drive the majority of horizontal consolidation, executing venture-to-venture acquisitions to broaden their enterprise product suites.
Furthermore, regulatory compliance creates operational barriers to direct biopharma buyouts of clinical digital health platforms:
Anti-Kickback Statute (AKS) and Fraud Oversight: If a pharmaceutical manufacturer owns a clinical telehealth platform that prescribes its own high-margin therapies, regulatory authorities may view the arrangement as an unlawful inducement. To manage this risk, platforms like LillyDirect and NovoCare maintain strict operational separation between manufacturer pricing portals and independent medical groups (e.g., Form Health).
Corporate Practice of Medicine (CPOM) Laws: Non-physician corporate entities are legally prohibited from practicing medicine or employing clinicians in many jurisdictions. Acquirers must utilize complex "Friendly PC-MSO" (Management Services Organization) corporate structures, where the biopharma-adjacent entity owns only the administrative MSO assets, not the clinical practice.
Antitrust Scrutiny: Federal antitrust regulators closely examine transactions where biopharma companies attempt to tie digital software tools to drug access, scrutinising potential foreclosure of market competition.
These regulatory constraints mean biopharma often prefers strategic partnerships, commercial licensing agreements, joint venture platforms, and corporate venture capital (CVC) investments over total equity buyouts for care-delivery platforms.
Conclusions and Strategic Outlook
Biopharma is not replacing traditional venture to venture consolidators or private equity buyers across the broader digital health market. However, it has established itself as an essential, capital-rich exit corridor and strategic anchor for digital health platforms operating at the intersection of therapeutic delivery, patient retention and advanced data analytics.
The convergence of biopharma’s $200 Bn+ loss-of-exclusivity patent cliff with the massive cash surpluses generated by GLP-1 therapies has permanently altered pharmaceutical commercialisation. To navigate patent expirations and maximise metabolic franchises, biopharma is transforming into a direct to patient platform operator.
For digital health executives, institutional investors and corporate strategists, navigating this landscape requires a targeted operational strategy:
Digital Health Founders: Companies building in the cardiometabolic, AI discovery, or clinical trial infrastructure sectors should architect their software platforms for seamless biopharma integration from inception. Developing defensible structural assets, such as independent clinical networks with specialised certifications, compliant EHR data-sharing layers and proven real world adherence protocols, creates clear acquisition appeal for biopharma buyers.
Venture Capital Investors: Exit underwriting must align with acquirer-specific demand. While generalist SaaS metrics may fail to secure public listings or high multiple venture to venture buyouts, platforms that directly support biopharma cash flows can command significant premiums. Investors should favour companies that integrate directly into direct-to-patient infrastructure, like LillyDirect and NovoCare, or those providing proprietary TechBio platforms.
Biopharma Corporate Development: As realised prices come under pressure and competition intensifies across oral GLP-1 and peptide categories, acquiring digital infrastructure is a strategic necessity. Biopharma M&A teams must actively acquire digital engagement and real-world evidence assets to protect gross margins, minimise patient drop-offs, and accelerate late-stage pipeline development.
Ultimately, while biopharma will not acquire every digital health startup, it is actively acquiring and capitalising the digital operating layers that determine how modern therapeutics are discovered, distributed, and sustained.
Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Follow Nelson Advisors LinkedIn Page > https://www.linkedin.com/company/nelson-advisors/
Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
#VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments